China Approves First Amino Acid Formula for PKU Patients Over 1

This approval marks a regulatory milestone for China's rare disease support infrastructure, addressing a critical nutritional void for PKU patients beyond infancy. It signals growing policy attention to specialized medical foods, which could encourage more domestic manufacturers to enter this niche market. The immediate impact is on patient access and quality of life, but the broader significance lies in whether this precedent accelerates the pipeline for other rare disease formulas. Watch for subsequent registrations and how the approval framework evolves for similar products.